Search

Lithium citrate

Vecuronium

Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or

Oxitriptan

the United Kingdom, United States and Canada as a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid, and is also marketed in many European countries for the indication … More study is needed to determine efficacy in treating depression.

Pretomanid

It was the first TB drug developed by a nonprofit organization, known as TB Alliance, and was granted FDA approval on August 14, 2019. … [A182915] Pretomanid is an antimycobacterial agent that is administered with [Bedaquiline] and [Linezolid] to treat resistant forms of pulmonary TB.

Nitrendipine

It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.

Ebola Zaire vaccine (live, attenuated)

Ervebo, the marketed Ebola virus vaccine by Merck, was first approved by the European Commission in November 2019 after the European Medicines Agency recommended it be licensed. … In December 2019, Ervebo was approved by the FDA in the United States.

Varlitinib

Over-expression of ErbB-2 and EGFR receptors in tumors is predictive of poor prognosis in cancer patients. … Varlitinib is an oral, selective, reversible, small molecule tyrosine kinase inhibitor of both ErbB-2 (Her-2/neu) and EGFR.

Fimasartan

Fimasartan is an angiotensin II receptor antagonist (ARB) drug employed in the treatment of both hypertension and heart failure. … It has been found to be safe when administered with hydrochlorothiazide (a diuretic) in clinical trials.

Celiprolol

In 2010 a clinical trial has suggested a use for this medication in the prevention of vascular complications of a rare inherited disease called vascular Ehlers–Danlos syndrome. … Celiprolol is not approved for use by the FDA in the treatment of vascular Ehlers–Danlos syndrome.

Tifuvirtide

It has received fast-track designation from the FDA and is in Phase I/II clinical testing.